Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Troglitazone is a new drug for the treatment of type 2 diabetes. Although mild liver injury occurred in 1.9% of participants in controlled trials, the U.S. Food and Drug Administration has received reports of five postmarketing cases of severe liver disease that resulted in death or liver transplantation. OBJECTIVE: To report the clinical and histopathologic characteristics of a patient with troglitazone-associated severe liver injury leading to transplantation. DESIGN: Case report. SETTING: Two university hospitals. PATIENT: A 55-year-old woman taking troglitazone, 400 mg/d, and insulin, 120 U/d. INTERVENTION: Discontinuation of troglitazone therapy, pretransplantation liver biopsy, and liver transplantation. RESULTS: Early nonspecific symptoms were attributed to other causes and were not evaluated. After the patient had used troglitazone for 3.5 months, massive loss of liver parenchyma and symptoms of liver failure developed, necessitating liver transplantation. CONCLUSION: Troglitazone may cause subfulminant liver failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, only pioglitazone is available; troglitazone was withdrawn from the market in 2000 and rosiglitazone was withdrawn in 2010 due to liver toxicity, drug-induced hepatitis352, 353, 354 and the increased risk of cardiovascular events, respectively.355”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [353]
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446 · cited 2×
“A recent summary of data from troglitazone clinical trials did not identify the possibility of troglitazone-induced hepatic failure (5).”
BackgroundTroglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
The Troglitazone study group, Kumar, S., Boulton, A. J. M., Beck-Nielsen, H., Berthezene, F., Muggeo, M., Persson, B., Spinas, G. A., Donoghue, S., Lettis, S., et al. (1996) · Diabetologia · doi:10.1007/bf00418542 · Cited by 236
Troglitazone Has a Scavenging Effect on Reactive Oxygen Species
Inoue, I., Katayama, S., Takahashi, K., Negishi, K., Miyazaki, T., Sonoda, M., & Komoda, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6512 · Cited by 96 · cited 1×
“dant stress (9, 10), but its ability to undergo single-”
BackgroundA Novel Antidiabetic Drug, Troglitazone — Reason for Hope and Concern
Imura, H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381311 · Cited by 57 · cited 1×
“Furthermore, it has been stated that troglitazone-induced changes in liver enzymes are largely mild and reversible (8).”
BackgroundCominacini, L., Garbin, U., Pastorino, A. M., Campagnola, M., Pasini, A., Davoli, A., Rigoni, A. M., & Cascio, V. L. (1997) · Diabetologia · doi:10.1007/s001250050658 · Cited by 48 · cited 1×
“dant stress (9, 10), but its ability to undergo single-”
Background
Cited by
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
Self-citationHewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
“It was withdrawn from the market because of liver toxicity and fulminant hepatic failure in several patients (Gitlin et al., 1998; Neuschwander-Tetri et al., 1998).”
Background
Metadata
- Authors
- Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1998-07-01
- Volume
- 129
- Issue
- 1
- Pages
- 38-41
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2013326347
- Cited by
- 195
- References
- 6
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 26.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- troglitazone, drug-induced liver injury, drug-induced liver failure, liver transplantation, thiazolidinediones, type 2 diabetes, adverse drug reactions, liver histopathology, insulin therapy
- MeSH terms
- Troglitazone, Chromans, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Middle Aged, Thiazoles, Liver Transplantation, Liver Failure, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report. https://app.cochat.ai/papers/10.7326/0003-4819-129-1-199807010-00009
- The paper
- Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998). Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-129-1-199807010-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.